Allan is the Founder and CSO of T-Therapeutics, and a world-renowned researcher and entrepreneur. He is Emeritus Director of the Wellcome Trust Sanger Institute and was responsible for transitioning its high-throughput genome-sequencing infrastructure into an academic genome centre with a focus on primary research.
Allan’s academic research formed the foundation in 2010 of the humanised antibody discovery company, Kymab Ltd which has resulted in the discovery of a number of novel antibodies that having demonstrated benefit in clinical trials. In January 2021, it was announced that Sanofi had acquired Kymab for $1.45 billion. This ground-breaking platform conceived at the Sanger Institute and developed through 10 years within Kymab formed the basis of the animal health company PetMedix that Allan co-founded in 2018.
In his academic role, Allan has published widely in high impact journals and is a respected expert in the monoclonal antibody and mouse engineering fields. Previously he was a Howard Hughes Medical Institute Investigator at Baylor College of Medicine (Houston, USA) where he built up one of the biggest transgenic mouse facilities in the USA and also spun out Lexicon Genetics, another successful pharmaceutical company based on mouse genetic technology. Lexicon’s $1bn debut on the NASDAQ was achieved 5 years after it was founded. Allan is a Fellow of the Royal Society.